Venaxis to Present at Three Upcoming Investor Conferences

          Venaxis to Present at Three Upcoming Investor Conferences

PR Newswire

CASTLE ROCK, Colo., Sept. 5, 2013

CASTLE ROCK, Colo., Sept. 5, 2013 /PRNewswire/ --Venaxis, Inc. (Nasdaq:
APPY), an in vitro diagnostic company focused on obtaining FDA clearance and
commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based
assay for identifying patients that are at low risk for appendicitis, today
announced it will present at the Rodman & Renshaw Annual Global Investment
Conference, to be held September 8 – 10, 2013, at the Millennium Broadway
Hotel in New York, the Craig-Hallum 4^th Annual Alpha Select Conference, to be
held September 26, 2013, at the Convene 730 3^rd Avenue in New York; as well
as the Aegis Capital Vegas Healthcare Conference, to be held September 26 –
28, 2013, at the Wynn Las Vegas Hotel.

Event:     Rodman & Renshaw Annual Global Investment Conference
Date:     Monday, September 9, 2013
Time:     3:40 pm (Eastern Time)
Location:  Millennium Broadway Hotel; New York, NY

           Craig-Hallum 4^th Annual Alpha Select Conference
Date:     Thursday, September 26, 2013
Time:     3:10 pm (Eastern Time)
Location:  Flatiron Room; Convene 730 3^rd Avenue; New York, NY

           Aegis Capital Vegas Healthcare Conference
Date:     Thursday, September 26, 2013
Time:     11:30 am (Mountain Time)
Location:  Wynn Las Vegas Hotel; Las Vegas, NV

Steve Lundy, President and CEO of Venaxis, will provide an overview of the
Company's business at the Rodman & Renshaw and Craig-Hallum Conferences, and
Don Hurd, Senior Vice President and Chief Commercial Officer of Venaxis, will
present at the Aegis Capital Conference. Mr. Lundy and Mr. Hurd will be
available to participate in one-on-one meetings with investors who are
registered to attend the respective conferences.

The Rodman & Renshaw presentation will be webcast. To access the webcast,
please visit the investor relations section of the Venaxis website at The webcast replay will remain available for 90 days
following each live presentation.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its CE Marked APPY1 Test, the Company's
rapid, protein biomarker-based assay for appendicitis. This unique
appendicitis test has projected high sensitivity and negative predictive value
and is being developed to aid in the identification of patients at low risk
for acute appendicitis, allowing for more conservative patient management. The
APPY1 Test is being developed initially for pediatric, adolescent and young
adult patients with abdominal pain, as this population is at the highest risk
for appendicitis and has the highest risk of long-term health effects
associated with CT imaging. While FDA clearance is being sought, an initial
launch for the APPY1 Test is ongoing in select European countries. For more
information, visit

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All
statements, other than statements of historical fact, included in this press
release that address activities, events or developments that Venaxis believes
or anticipates will or may occur in the future are forward-looking statements.
These statements are based on certain assumptions made based on experience,
expected future developments and other factors Venaxis believes are
appropriate in the circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the control of
Venaxis. Investors are cautioned that any such statements are not guarantees
of future performance. Actual results or developments may differ materially
from those projected in the forward-looking statements as a result of many
factors, including our ability to successfully complete required product
development and modifications in a timely and cost effective manner, complete
clinical trial activities for the APPY1 Test required for FDA submission,
obtain FDA clearance or approval, maintain CE Marking, cost effectively
manufacture and generate revenues from the APPY1  Test at a profitable price
point, execute agreements required to successfully advance the company's
objectives, retain the management team to advance the products, overcome
adverse changes in market conditions and the regulatory environment, obtain
and enforce intellectual property rights, and realize value of intangible
assets. Furthermore, Venaxis does not intend (and is not obligated) to update
publicly any forward-looking statements. The contents of this press release
should be considered in conjunction with the risk factors contained in
Venaxis' recent filings with the SEC, including its Form 10-Q for the quarter
ended June 30, 2013.

For Investors and Media:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, PhD; (212) 375-2664

Claire Sojda; (212) 375-2686

SOURCE Venaxis, Inc.

Press spacebar to pause and continue. Press esc to stop.